This is probably the best question ever asked on t
Post# of 154678
(Total Views: 618)
Posted On: 05/14/2025 7:31:49 AM
This is probably the best question ever asked on this Board, so I got excited and asked ChatGPT. Be sure to read the last paragraph.
If metastasis turns out to be a RANTES (CCL5)-driven disease, it would represent a paradigm shift in oncology, with sweeping implications for both cancer biology and clinical treatment.
Here's a breakdown of the key implications:
???? 1. Understanding the Biology
RANTES (CCL5) is a chemokine involved in immune cell trafficking and inflammation. If metastasis is fundamentally driven by RANTES, it suggests:
CCR5 (the RANTES receptor) is a master regulator of metastatic spread.
Tumors may hijack RANTES signaling to recruit tumor-promoting immune cells (e.g., M2 macrophages, Tregs), evade immune surveillance, and remodel the microenvironment.
RANTES could play a central role in angiogenesis, cell migration, and preparing distant metastatic niches.
This would mean we’ve been targeting downstream effects (like angiogenesis or PD-L1 expression) rather than the root cause.
???? 2. Therapeutic Revolution
If true, blocking RANTES–CCR5 could:
Prevent or halt metastasis across multiple cancer types, not just one.
Reduce immune suppression in the tumor microenvironment.
Potentially synergize with immunotherapies, checkpoint inhibitors, and ADCs.
Drugs like leronlimab, a CCR5 antagonist, would shift from being "interesting" to foundational cancer therapies, akin to what Herceptin was to HER2+ breast cancer.
???? 3. Retrospective Reinterpretation of Data
It could explain:
Why some metastatic patients respond to certain drugs despite low biomarker expression.
Why immunotherapies work better in “hot” tumors (RANTES may help drive that cold-to-hot switch).
Why cancers metastasize preferentially to certain organs—RANTES gradients could act as a homing signal.
???? 4. Diagnostics and Monitoring
Circulating levels of CCL5 or CCR5+ immune cells could become biomarkers of metastatic risk.
CTC (Circulating Tumor Cell) profiling might focus more on CCR5 expression or RANTES responsiveness.
???? 5. New Research Priorities
Scientists would need to re-map the cancer signaling network with CCR5/RANTES at the center.
Clinical trials would shift to test CCR5 blockers in combination with existing standards of care across solid tumors.
???? Bottom Line
If metastasis is a RANTES disease, everything changes:
Targeting RANTES/CCR5 becomes the centerpiece of anti-metastatic strategy.
Survival could improve not by shrinking tumors, but by stopping their spread.
A drug like leronlimab could become oncology’s first broad-spectrum anti-metastasis agent.
This wouldn’t just be big.
It would be transformational.
If metastasis turns out to be a RANTES (CCL5)-driven disease, it would represent a paradigm shift in oncology, with sweeping implications for both cancer biology and clinical treatment.
Here's a breakdown of the key implications:
???? 1. Understanding the Biology
RANTES (CCL5) is a chemokine involved in immune cell trafficking and inflammation. If metastasis is fundamentally driven by RANTES, it suggests:
CCR5 (the RANTES receptor) is a master regulator of metastatic spread.
Tumors may hijack RANTES signaling to recruit tumor-promoting immune cells (e.g., M2 macrophages, Tregs), evade immune surveillance, and remodel the microenvironment.
RANTES could play a central role in angiogenesis, cell migration, and preparing distant metastatic niches.
This would mean we’ve been targeting downstream effects (like angiogenesis or PD-L1 expression) rather than the root cause.
???? 2. Therapeutic Revolution
If true, blocking RANTES–CCR5 could:
Prevent or halt metastasis across multiple cancer types, not just one.
Reduce immune suppression in the tumor microenvironment.
Potentially synergize with immunotherapies, checkpoint inhibitors, and ADCs.
Drugs like leronlimab, a CCR5 antagonist, would shift from being "interesting" to foundational cancer therapies, akin to what Herceptin was to HER2+ breast cancer.
???? 3. Retrospective Reinterpretation of Data
It could explain:
Why some metastatic patients respond to certain drugs despite low biomarker expression.
Why immunotherapies work better in “hot” tumors (RANTES may help drive that cold-to-hot switch).
Why cancers metastasize preferentially to certain organs—RANTES gradients could act as a homing signal.
???? 4. Diagnostics and Monitoring
Circulating levels of CCL5 or CCR5+ immune cells could become biomarkers of metastatic risk.
CTC (Circulating Tumor Cell) profiling might focus more on CCR5 expression or RANTES responsiveness.
???? 5. New Research Priorities
Scientists would need to re-map the cancer signaling network with CCR5/RANTES at the center.
Clinical trials would shift to test CCR5 blockers in combination with existing standards of care across solid tumors.
???? Bottom Line
If metastasis is a RANTES disease, everything changes:
Targeting RANTES/CCR5 becomes the centerpiece of anti-metastatic strategy.
Survival could improve not by shrinking tumors, but by stopping their spread.
A drug like leronlimab could become oncology’s first broad-spectrum anti-metastasis agent.
This wouldn’t just be big.
It would be transformational.
(15)
(0)